• Pfizer Industry News

  • 著者： Quiet. Please
  • ポッドキャスト

Pfizer Industry News

著者： Quiet. Please
無料で聴く

  • サマリー

  • Stay informed with "Pfizer Industry News," your go-to source for the latest updates and insights on Pfizer's innovations, pharmaceutical advancements, and industry trends. Join us as we explore breakthrough therapies, corporate developments, and expert interviews, keeping you ahead in the dynamic world of healthcare and medicine.

    For more info go to
    https://www.quietperiodplease....

    Check out these deals https://amzn.to/48MZPjs


    https://podcasts.apple.com/us/...
    Copyright 2024 Quiet. Please
    続きを読む 一部表示

あらすじ・解説

Stay informed with "Pfizer Industry News," your go-to source for the latest updates and insights on Pfizer's innovations, pharmaceutical advancements, and industry trends. Join us as we explore breakthrough therapies, corporate developments, and expert interviews, keeping you ahead in the dynamic world of healthcare and medicine.

For more info go to
https://www.quietperiodplease....

Check out these deals https://amzn.to/48MZPjs


https://podcasts.apple.com/us/...
Copyright 2024 Quiet. Please
続きを読む 一部表示
エピソード
  • Pfizer's 2025 Outlook: Moderate Stability or Volatility Ahead?

    Pfizer's 2025 Outlook: Moderate Stability or Volatility Ahead?
    2025/01/11
    Pfizer's stock price as of January 8, 2025, is $26.86[1]. The current price is below the 52-week high of $31.54 and above the 52-week low of $24.48, indicating a moderate position within its recent trading range.

    Recent trading volume data is not provided in the available sources, but it is crucial to consider this factor for a comprehensive analysis. Typically, high trading volumes compared to the average can indicate significant investor interest or potential volatility.

    There are no recent news or announcements about Pfizer or its stock mentioned in the provided sources. However, analyst updates and price target changes are available. The consensus price target among analysts is $32.00, with a forecasted upside of 18.87% from the current price[2]. Some analysts, such as Truist Securities, have set a price target of $32.00, expecting a 19.54% upside within the next 12 months[3].

    Other forecasts vary significantly. CoinPriceForecast predicts a price range of $31.12 to $31.61 in 2025, indicating steady growth[4]. In contrast, PandaForecast anticipates a broader range of $26.46 to $40.15, with significant increases throughout the year[4]. LongForecast provides a detailed monthly forecast for 2025, starting with a range of $24.20 to $29.21 in January and ending with a range of $35.69 to $41.89 in December[5].

    In summary, Pfizer's stock is currently trading at $26.86, with analysts predicting a potential upside of 18.87% to $32.00. Various forecasts suggest a range of possible outcomes, from steady growth to significant increases throughout 2025. Investors should consider these predictions along with recent trading volumes and any upcoming news or announcements for a comprehensive understanding of Pfizer's stock performance.
    続きを読む 一部表示
    2 分
  • Pfizer's Promising Future: Exploring Analyst Insights and Stock Forecasts for 2025

    Pfizer's Promising Future: Exploring Analyst Insights and Stock Forecasts for 2025
    2025/01/11
    Pfizer's stock, trading under the symbol PFE, has been a subject of interest for investors and analysts alike. As of January 11, 2025, the most recent closing stock price for Pfizer is 26.86 dollars[1].

    In terms of trading volume, specific data on the current trading volume versus the average is not provided in the available sources. However, historical data indicates that Pfizer's stock has experienced fluctuations in trading volume, which can be influenced by various market and company-specific factors.

    Recent news and announcements about Pfizer include the company's ongoing efforts in the pharmaceutical industry, particularly in developing new treatments and vaccines. However, specific recent news or announcements are not detailed in the provided sources.

    Major analyst updates and price target changes include a consensus price target of 32 dollars, representing an 18.87% upside from the current price, according to 16 analysts[2]. Another source indicates a consensus price target of 37.09 dollars based on the ratings of 24 analysts, with the high being 60 dollars issued by Goldman Sachs and the low being 25 dollars issued by Wolfe Research[3].

    Other relevant information includes forecasts from various sources. WalletInvestor predicts a slight decline in Pfizer stock in 2025, with a forecast ranging from 23.837 to 28.105 dollars[4]. In contrast, PandaForecast anticipates sustained growth throughout 2025, with prices potentially reaching 40.15 dollars by December[4]. LongForecast provides a detailed monthly forecast for 2025, indicating a steady increase in the stock price, starting from 26.53 dollars in January and reaching 38.79 dollars by December[5].

    Overall, Pfizer's stock forecast is cautiously optimistic, with analysts anticipating potential growth driven by the company's strong product lineup and promising new treatments and vaccines. However, investors should note the industry's sensitivity to regulatory shifts, competitive dynamics, and broader economic factors, which can influence stock trajectories.
    続きを読む 一部表示
    2 分
  • Pfizer Stock Outlook 2025: Navigating Challenges and Opportunities

    Pfizer Stock Outlook 2025: Navigating Challenges and Opportunities
    2025/01/10
    Pfizer's stock price as of January 10, 2025, is $26.94, with a 0.3% increase during mid-day trading. The company traded as high as $27.00 and last traded at $26.94, with 10,932,240 shares traded, a decline of 65% from the average session volume of 31,681,477 shares[5].

    Recent trading volume has been lower than average. On January 8, 2025, 31,721,568 million shares traded, but by January 10, 2025, this number decreased to 10,932,240 shares[2][5].

    Several analysts have recently updated their ratings and price targets for Pfizer. Wolfe Research initiated coverage with an "underperform" rating and a $25.00 price objective. Evercore ISI raised Pfizer to a "strong-buy" rating. Guggenheim reduced their price objective from $35.00 to $33.00 and set a "buy" rating. UBS Group reduced their price target from $31.00 to $29.00 and set a "neutral" rating. The company currently has an average rating of "Moderate Buy" and an average target price of $32.00[5].

    Pfizer reported $18 billion in revenue and $1.06 earnings per share in the last quarter, beating revenue expectations by $3 billion and exceeding earnings estimates by $0.44[2].

    The long-term outlook for Pfizer stock is cautiously optimistic, with potential growth driven by the company's strong product lineup and promising new treatments and vaccines. However, the industry is sensitive to regulatory shifts, competitive dynamics, and broader economic factors[4].

    Analysts predict a range of outcomes for Pfizer's stock price in 2025, from a decline to $24.897 by WalletInvestor to an increase to $31.61 by CoinPriceForecast and $40.15 by PandaForecast[4]. The average 12-month price forecast from 12 analysts is $32.17, predicting a 19.77% increase from the current stock price[3].
    続きを読む 一部表示
    2 分

Pfizer Industry Newsに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。